- Home
- OFS vs DXR Comparison
OFS vs DXR Comparison
Compare OFS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | DXR |
|---|---|---|
| Founded | 2001 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 61.1M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | OFS | DXR |
|---|---|---|
| Price | $4.55 | $13.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 113.2K | 2.6K |
| Earning Date | 10-30-2025 | 02-27-2026 |
| Dividend Yield | ★ 14.78% | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | 0.24 | ★ 0.36 |
| Revenue | ★ $42,970,000.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $19.08 | $38.33 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.44 | $6.55 |
| 52 Week High | $9.80 | $14.15 |
Technical Indicators
Market Signals| Indicator | OFS | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 62.36 |
| Support Level | $4.44 | $12.00 |
| Resistance Level | $4.66 | $12.90 |
| Average True Range (ATR) | 0.26 | 0.38 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 17.20 | 97.95 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.